Know Cancer

or
forgot password

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver


Phase 1
N/A
N/A
Not Enrolling
Both
Colorectal Neoplasm, Liver Neoplasm, Neoplasm Metastasis

Thank you

Trial Information

A Phase I Study of Isolated Hepatic Perfusion With Escalating Dose Melphalan Followed by Postoperative Hepatic Arterial Floxuridine and Leucovorin for Metastatic Unresectable Colorectal Cancers of the Liver


Patients with unresectable metastatic colorectal cancer confined to the liver will undergo a
1 hour hyperthermic isolated hepatic perfusion (IHP) with escalating dose melphalan.
Postoperatively, patients will be treated with hepatic arterial infusion of floxuridine
(FUDR), 0.2 mg/kg/day and leucovorin (LV), 15 mg/M(2)/day as a 2-week continuous infusion
regimen. Hepatic and systemic toxicity, response to treatment, duration of response, and
survival will be followed.

Inclusion Criteria


Histologically or cytologically proven measurable metastatic colorectal cancer limited to
the parenchyma of the liver with no evidence of unresectable extrahepatic disease by
preoperative radiological studies. Limited resectable extrahepatic disease is acceptable.

Patients must not have been previously treated with intrahepatic artery infusional therapy
using FUDR.

Patients mush have had no chemotherapy, radiotherapy or biologic therapy for their
malignancy in the month prior to the liver perfusion and must have recovered from all side
effects.

Patients must have an ECOG performance standard of 0, 1 or 2 on the day prior to
treatment.

Patients must have adequate hepatic function as evidence by bilirubin less than 2.0 and a
PT and PTT that are within 1-2 seconds of the upper normal limit.

Patients must not have biopsy proven cirrhosis or evidence of significant portal
hypertension by history, endoscopy, or radiologic studies.

Patients must not have a history of congestive heart failure with an LVEF less than 40%.

Patients must not have COPD or other chronic pulmonary disease with PFT's less than 50%
predicted for age.

Patients must be 18 years of age or older.

Patients must have a platelet count greater than 100,000 a Hct greater than 27.0, a white
blood count greater than 3000/micro liters, and a creatinine less than or equal to 1.5 or
a creatinine clearance of greater than 60 ml/min.

Patients must not be pregnant or nursing.

Patients must not be taking immunosuppressive drugs or on chronic anticoagulation.

Patients must not have an active infection.

Patients must not have severe allergic reactions to iodine contrast which can not be
controlled by premedication with antihistamines and steroids.

Patients must not have HIV disease.

Patients must be aware of the neoplastic nature of his/her illness, the experimental
nature of the therapy, alternative treatments, potential benefits, and risks. The patient
must be willing to sign an informed consent.

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Primary Purpose: Treatment

Authority:

United States: Federal Government

Study ID:

970111

NCT ID:

NCT00001576

Start Date:

July 1997

Completion Date:

March 2002

Related Keywords:

  • Colorectal Neoplasm
  • Liver Neoplasm
  • Neoplasm Metastasis
  • Regional Therapy
  • Organ Perfusion
  • Metastases
  • Hyperthermia
  • Neoplasms
  • Colorectal Neoplasms
  • Liver Neoplasms
  • Neoplasm Metastasis

Name

Location

National Cancer Institute (NCI)Bethesda, Maryland  20892